Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2026)

Barinthus Biotherapeutics has reported Operating Expenses for 7 years, with the latest figure at $6.1 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses fell 70.75% year-over-year to $6.1 million; the trailing twelve-month figure through Mar 2026 stood at $56.3 million (down 36.02% YoY), and the FY2025 full-year result was $71.1 million, down 15.52% from the prior year.
• Operating Expenses for Q1 2026 stood at $6.1 million, down from $11.6 million in the prior quarter.
• The five-year high for Operating Expenses was $31.6 million in Q4 2022, with the low at -$1.1 million in Q3 2022.
• Historically, Operating Expenses has averaged $17.3 million across 5 years, with a median of $18.9 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses tumbled 119.28% — and 2023, when it soared 1603.73%.
• Barinthus Biotherapeutics' Operating Expenses stood at $31.6 million in 2022, then slumped by 36.65% to $20.0 million in 2023, then gained by 17.94% to $23.6 million in 2024, then sank by 50.91% to $11.6 million in 2025, then plunged by 47.11% to $6.1 million in 2026.
• The last three Operating Expenses figures came in at $6.1 million (Q1 2026), $11.6 million (Q4 2025), and $15.2 million (Q3 2025), per Business Quant data.